标题
Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
作者
关键词
-
出版物
Expert Opinion on Drug Metabolism & Toxicology
Volume 14, Issue 4, Pages 447-460
出版商
Informa UK Limited
发表日期
2018-04-05
DOI
10.1080/17425255.2018.1461835
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
- (2017) Yan Xie et al. BMJ Open
- A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors
- (2016) A. G. Clooney et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis
- (2016) Hitomi Ichikawa et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Effect of proton pump inhibitors and antibiotics on the gut microbiome of hospitalised older persons
- (2016) Caoilfhionn O'Donoghue et al. JOURNAL OF INFECTION
- Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
- (2016) Benjamin Lazarus et al. JAMA Internal Medicine
- Adverse Effects Associated With Proton Pump Inhibitors
- (2016) Adam Jacob Schoenfeld et al. JAMA Internal Medicine
- Association of Proton Pump Inhibitors With Risk of Dementia
- (2016) Willy Gomm et al. JAMA Neurology
- Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis
- (2016) Yingxi Chen et al. PLoS One
- Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis
- (2015) Javier Molina-Infante et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
- (2015) Henry M. Dunnenberger et al. Annual Review of Pharmacology and Toxicology
- Proton-pump inhibitors and risk of fractures: an update meta-analysis
- (2015) B. Zhou et al. OSTEOPOROSIS INTERNATIONAL
- Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies
- (2015) Wisit Cheungpasitporn et al. RENAL FAILURE
- First-line eradication forHelicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced byCYP2C19genotype
- (2015) Yoshimasa Saito WORLD JOURNAL OF GASTROENTEROLOGY
- Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis
- (2015) Allison A. Lambert et al. PLoS One
- Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole
- (2014) S. Sahara et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Clinical pharmacogenetics implementation: Approaches, successes, and challenges
- (2014) Kristin W. Weitzel et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS
- Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese
- (2014) Mitsushige Sugimoto et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene–drug pairs
- (2014) John J Lima et al. PHARMACOGENOMICS
- Efficacy of tailoredHelicobacter pylorieradication therapy based on antibiotic susceptibility andCYP2C19genotype
- (2014) Mitsushige Sugimoto WORLD JOURNAL OF GASTROENTEROLOGY
- Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease
- (2013) Philip O Katz et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Association of CYP2C19 Polymorphisms and Lansoprazole-Associated Respiratory Adverse Effects in Children
- (2013) John J. Lima et al. JOURNAL OF PEDIATRICS
- Gastroesophageal Reflux: Management Guidance for the Pediatrician
- (2013) J. R. Lightdale et al. PEDIATRICS
- Institutional Profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics
- (2013) Julie A Johnson et al. PHARMACOGENOMICS
- Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials
- (2013) Hui-Lin Tang et al. PLoS One
- Proton Pump Inhibitors in Pediatrics
- (2013) Robert M. Ward et al. PEDIATRIC DRUGS
- Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
- (2013) Jai Moo Shin et al. Journal of Neurogastroenterology and Motility
- Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis
- (2012) Chun Shing Kwok et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Absorption, Distribution, Metabolism and Excretion of [14C]Dexlansoprazole in Healthy Male Subjects
- (2012) Brian Grabowski et al. CLINICAL DRUG INVESTIGATION
- Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array
- (2012) J A Johnson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project
- (2012) J M Pulley et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics
- (2012) P H O'Donnell et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenomics Knowledge for Personalized Medicine
- (2012) M Whirl-Carrillo et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
- (2012) Barbara Gawrońska-Szklarz et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Lansoprazole for Children With Poorly Controlled Asthma: A Randomized Controlled Trial
- (2012) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!
- (2012) C. Scarpignato NEUROGASTROENTEROLOGY AND MOTILITY
- Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection
- (2011) C. Bavishi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pharmacogenetics: From Bench to Byte— An Update of Guidelines
- (2011) J J Swen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
- (2011) M V Relling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype–phenotype correlation in childhood
- (2011) Ersin Gumus et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- PharmGKB summary
- (2011) Stuart A. Scott et al. Pharmacogenetics and Genomics
- Update on the pharmacogenomics of proton pump inhibitors
- (2011) Krisztina Hagymási et al. PHARMACOGENOMICS
- Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping
- (2010) S. Miehlke et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole
- (2010) Barbara Gawrońska-Szklarz et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD)
- (2010) Robert M. Ward et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A Multicenter, Randomized, Open-Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux Disease
- (2010) Robert M. Ward et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics
- (2010) Laurent Becquemont et al. PHARMACOGENOMICS
- A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism
- (2009) N. G. HUNFELD et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Rabeprazole
- (2009) Claudine M. Baldwin et al. DRUGS
- CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole
- (2009) Takahisa Furuta et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
- (2008) Katsuyoshi Sugimoto et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of CYP2C19 *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians
- (2008) Nicole G. Hunfeld et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenetics: From Bench to Byte
- (2008) JJ Swen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism
- (2008) Horng-Yuan Lou et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Proton pump inhibitors: an update of their clinical use and pharmacokinetics
- (2008) Shaojun Shi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor-Based Triple Therapy forHelicobacter pyloriEradication: A Meta-Analysis
- (2008) Fujun Zhao et al. HELICOBACTER
- Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Assessing the Efficacy and Safety of Proton Pump Inhibitor Lansoprazole in Infants with Symptoms of Gastroesophageal Reflux Disease
- (2008) Susan R. Orenstein et al. JOURNAL OF PEDIATRICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now